|
Topics in Evidence-Based Pharmacy Practice
11/15/2010: Once Weekly Exenatide, Sitagliptin, or Pioglitazone for Adjunct Therapy to Metformin
Theresa Castillo
Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas
Daniel Vu
Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas
Amy P. Witte
Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas
Excerpt:"Type 2 diabetes mellitus (T2DM) is a chronic disease that, when uncontrolled, can result in significant diabetes-related complications.1 Guidelines recommend metformin as first line therapy, but additional treatment is often necessary to achieve desired goals. New treatments such as glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to have a beneficial effect on metabolic abnormalities such as obesity, hypertension, and dyslipidemia. However, the extent of the benefits as compared to other classes of drugs such as insulin, sulphonylureas, and thiazolidinediones has been questionable.2..."
|
|
|
|
|